← Back to patent-cliff list
Repinatrabit
Tier C — Watch / tradeRepinatrabit
Jnana Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SLC6A19
Indications (approved)：高苯丙氨酸血症
Regional status
US
Phase III
2025-08-11
EU
Phase III
2025-10-20
China
-
Japan
Phase III
2025-10-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Repinatrabit?
Approved indications include: 高苯丙氨酸血症.
When does the Repinatrabit patent expire?
No public expiry year is available for Repinatrabit yet; this page updates once verified.
How do I get a quote for Repinatrabit intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30